Progress in Neuro-Psychopharmacology and Biological Psychiatry
Neuropsychological correlates of the P300 in patients with Alzheimer's disease
Highlights
► The P300 amplitude has reduced in AD patients. ► The P300 amplitude reflects executive, language, and memory function in AD patients. ► P300 latency reflects global cognition and attention deficit in AD patients. ► The P300 indices could be used as a biological marker in AD patients.
Introduction
Alzheimer disease (AD), one of the most common causes of mental deterioration in the elderly, is a progressive neurodegenerative disorder that is characterized by cognitive and behavioral dysfunction. This disease has a slow onset and gradual progression. Early treatment is needed for better treatment outcome; therefore, an early diagnosis of the condition is very important. Although the biological methods used to diagnose and evaluate AD patients are still very rudimentary (Kim et al., 2012), the P300 component of event-related potentials (ERPs) has been used to study dementia and aging (Polich, 2007). There are some distinguishable ERP components in the time range of the P3 wave, specifically a frontally maximal P3a component and a parietally maximal P3b component. The P3a component is characterized by an infrequent, distinct tone presented in a series of frequent tones without a task. The P3b component is a task-relevant potential elicited during target stimulus processing. When ERP researchers refer to the P3 component, they usually mean the P3b component (Luck, 2005, Polich, 2007). The P300 component is easy to observe and reflects both attention and working memory processing (Polich, 2007). Polich et al. reported that the amplitude of P300 was smaller and that the peak latency was longer in AD patients compared to control subjects (Polich et al., 1990). The P300 has been revealed as a sensitive tool to detect the progress of AD in the initial stage (Polich and Corey-Bloom, 2005), and similar findings were found in minimal cognitive impairment (MCI) patients (Frodl et al., 2002, Golob et al., 2002, Golob et al., 2007).
Lai et al. (2010) investigated the P300 of probable AD patients, MCI patients, and normal controls in a 1-year prospective study. The cognitive abilities screening instrument (CASI) test was used to screen the patients (Cullen et al., 2007). In this study, the P300 amplitude reduction and CASI score changes failed to reach statistical significance between the baseline and the follow-up in probable AD and MCI patients; however, the P300 latencies were significantly more delayed in the follow-up (Lai et al., 2010). In general, the P300 amplitude and latency have been revealed as sensitive markers that indicate the progress of cognitive dysfunction in AD patients (Ball et al., 1989, Polich et al., 1986).
The diagnosis of AD is heavily dependent on the neuropsychological test scores of suspected AD subjects. There are relatively few studies, however, that have systematically investigated the relationship between neuropsychological tests and P300 parameters. A larger P300 amplitude has been related to better short- (Verleger, 1988) and long-term memory function (Johnson et al., 1985). Additionally, significant positive correlations were observed between the P300 amplitude and neuropsychological tests, such as verbal IQ, the Wechsler Memory Scale (Lee et al., 1994), digit span (Fjell and Walhovd, 2001), and the Trail Making Test part B (TMT-B), in healthy subjects (Lee et al., 1994) and obsessive–compulsive disorder patients (Kim et al., 2003). In sum, the P300 amplitude has been shown to be highly correlated with neuropsychological test scores, such as the TMT-B, the Wechsler Memory Scale, and digit span, in patients with several neuropsychiatric illnesses and in healthy controls.
The P300 latency indicates the stimulus classification speed (Katada et al., 2003) and the increased cognitive load (Reza et al., 2006), but it is not generally related to the response selection processes (McCarthy and Donchin, 1981, Pfefferbaum et al., 1986). The P300 latency indicates how long it takes to process information before making a response; therefore, it has often been considered a sensitive temporal index of the neural activity underlying the processes of attention allocation and immediate memory (Polich, 2007). The P300 latency increases as cognitive capability decreases in AD patients (Lai et al., 2010) and is also significantly correlated with neuropsychological tests, such as the TMT-B (Kim et al., 2003), the Stroop task (Kindermann et al., 2000), the Wechsler Adult Intelligence Scale (Liu et al., 2007), and verbal fluency (Souza et al., 1995). Thus, the P300 latency may play an important role in indicating the cognitive dysfunction associated with AD (Katada et al., 2003). To date, no studies have directly evaluated the relationship between the P300 indices and multiple diagnostic neuropsychological tests in AD patients.
Various neuropsychological tests have been used widely for the diagnosis of AD in clinical practices. Recently, the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) also developed standardized clinical and neuropsychological assessment batteries to evaluate patients with AD. Although it is important to make a psychophysiological validation of each neuropsychological test in the CERAD package, it has not been tested in a clinical sample yet. If there is a significant relationship between the neuropsychological tests of CERAD and the P300 parameters, it will provide clinically valuable information for diagnosing dementia. In this study, we hypothesized that changes in the P300 (i.e., reduced amplitude and delayed latencies) would be correlated with the neuropsychological tests of the CERAD in AD patients, thereby providing evidence that the P300 could be used as a biological marker of the cognitive dysfunction associated with AD. In the present study, we have correlated the P300 with the CERAD-K (the Korean version) neuropsychological tests in patients with AD and age- and education-matched normal controls to evaluate the clinical implication of the P300 in AD patients. If significant correlations exist, we may be able to monitor the progress of AD or the effects of therapeutic interventions in AD patients by measuring the P300.
Section snippets
Participants
Patients with AD and healthy controls were recruited from the Psychiatry Department of Inje University, Ilsan Paik Hospital, Korea. The AD patients were diagnosed as probable AD by the structured diagnostic evaluation using the CERAD-K (Lee et al., 2002) on the basis of the National Institute of Neurological and Communication Disorders and the Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984). The Clinical Dementia Rating Scale (CDR) (
Demographic data and neuropsychological test results
Thirty-one AD patients and 31 NC were recruited. Age (AD: 76.45 ± 5.57 years, NC: 75.84 ± 4.74 years) and education level (AD: 5.0 ± 5.36 years, NC: 5.13 ± 3.72) did not differ significantly between the AD patients and the NC subjects. The AD patients were classified as having mild AD (N = 18, CDR score: 0.5 or 1), moderate AD (N = 9, CDR score: 2) or severe AD (N = 4, CDR score: ≥ 3). The mean scores of all subset tests of the CERAD-K (verbal fluency, K-BNT, MMSE-KC, SBT-K, word list memory, constructional
Discussion
The P300 amplitude was significantly decreased in the AD patients compared to the NC subjects, as observed in almost all of the electrodes. Our results are consistent with previous studies that reported a decreased P300 amplitude in AD patients (Boller et al., 2002, Frodl et al., 2002, Yamaguchi et al., 2000). Ally et al. (2006) reported that the P300 amplitude was significantly decreased in AD patients compared to age- and gender-matched normal controls. Additionally, their biological children
Acknowledgements
This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (no. A08-4117-A22023-08N1-00010A).
References (73)
- et al.
The P300 component in patients with Alzheimer's disease and their biological children
Biol Psychol
(2006) - et al.
Source imaging of P300 auditory evoked potentials and clinical correlations in patients with posttraumatic stress disorder
Prog Neuropsychopharmacol Biol Psychiatry
(2011) - et al.
Revisiting P300 cognitive studies for dementia diagnosis: early dementia with Lewy bodies (DLB) and Alzheimer disease (AD)
Neurophysiol Clin
(2010) - et al.
Revisiting P300 cognitive studies for dementia diagnosis: early dementia with Lewy bodies (DLB) and Alzheimer disease (AD)
Neurophysiol Clin
(2010) - et al.
Multi-voxel pattern analysis of fMRI data predicts clinical symptom severity
Neuroimage
(2011) - et al.
Effects of mnemonic strategy manipulation in a Von Restorff paradigm
Electroencephalogr Clin Neurophysiol
(1990) - et al.
P300 amplitude in non-bipolar, melancholic depression
J Affect Disord
(1993) - et al.
Auditory event-related potentials during target detection are abnormal in mild cognitive impairment
Clin Neurophysiol
(2002) - et al.
A voxel-based morphometric study of ageing in 465 normal adult human brains
Neuroimage
(2001) - et al.
Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment
Neurobiol Aging
(2011)